Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2023年 / 20卷 / 12期
关键词：
CISPLATIN; CHEMOTHERAPY; CANCER; UNFIT;
D O I：
10.1038/s41571-023-00814-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin-ineligible, herein we highlight key clinical outcomes with this combination based on results from Cohort K of the pivotal phase Ib/II EV-103 trial. We also discuss treatment sequencing, de-escalation strategies and toxicity management as EV-pembrolizumab becomes widely used in clinical practice.
引用
收藏
页码：818 / 819
页数：2
相关论文
共 50 条
  • [21] Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study
    Taguchi, Satoru
    Kawai, Taketo
    Ambe, Yoshiki
    Kishitani, Kenjiro
    Sugimoto, Kazuma
    Miyakawa, Jimpei
    Nakamura, Yu
    Noda, Michio
    Kaneko, Tomoyuki
    Kamei, Jun
    Obinata, Daisuke
    Yamaguchi, Kenya
    Kakutani, Shigenori
    Furuya, Yoshitsune
    Sato, Yujiro
    Uemura, Yukari
    Akiyama, Yoshiyuki
    Yamada, Yuta
    Sato, Yusuke
    Yamada, Daisuke
    Enomoto, Yutaka
    Nishimatsu, Hiroaki
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Nakagawa, Tohru
    Takahashi, Satoru
    Kume, Haruki
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, : 1180 - 1186
  • [22] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Takahashi, Shunji
    Uemura, Motohide
    Kimura, Tomokazu
    Kawasaki, Yoshihide
    Takamoto, Atsushi
    Yamaguchi, Akito
    Melhem-Bertrandt, Amal
    Gartner, Elaina M.
    Inoue, Takashi
    Akazawa, Rio
    Kadokura, Takeshi
    Tanikawa, Toshiki
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1056 - 1066
  • [23] Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
    Li, Andong
    Wu, Meiyu
    Xie, Ouyang
    Xiang, Heng
    Meng, Kehui
    Tan, Chongqing
    Wang, Long
    Wan, Xiaomin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
    Sayegh, Nicolas
    Jo, Yeonjung
    Gebrael, Georges
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Chehade, Chadi Hage
    Mahlow, Jon
    Maughan, Benjamin L.
    Gupta, Sumati
    Agarwal, Neeraj
    Swami, Umang
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [25] Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era
    Kita, Yuki
    Ito, Katsuhiro
    Sano, Tomoyasu
    Hashimoto, Kohei
    Mochizuki, Takanori
    Shiraishi, Yusuke
    Araki, Hiromasa
    Fujiwara, Maki
    Kanamaru, Sojun
    Takahashi, Takehiro
    Hishiki, Kosuke
    Okada, Takuya
    Ogawa, Kosuke
    Ito, Masaaki
    Kojima, Takahiro
    Nishiyama, Naotaka
    Matsui, Yoshiyuki
    Nishiyama, Hiroyuki
    Kitamura, Hiroshi
    Kobayashi, Takashi
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (07) : 647 - 655
  • [26] Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study
    Taoka, Rikiya
    Kamada, Masaki
    Izumi, Kazuyoshi
    Tanimoto, Ryuta
    Daizumoto, Kei
    Hayashida, Yushi
    Uematsu, Katsutoshi
    Arai, Hironobu
    Sano, Takeshi
    Saito, Ryoichi
    Hirama, Hiromi
    Kobayashi, Toshihiro
    Honda, Tomoko
    Osaki, Yu
    Abe, Yohei
    Naito, Hirohito
    Tohi, Yoichiro
    Matsuoka, Yuki
    Kato, Takuma
    Okazoe, Homare
    Ueda, Nobufumi
    Sugimoto, Mikio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 602 - 611
  • [27] The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
    McGregor, B. A.
    Sonpavde, G. P.
    Kwak, L.
    Regan, M. M.
    Gao, X.
    Hvidsten, H.
    Mantia, C. M.
    Wei, X. X.
    Berchuck, J. E.
    Berg, S. A.
    Ravi, P. K.
    Michaelson, M. D.
    Choueiri, T. K.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 91 - 97
  • [28] Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin
    Kobatake, Kohei
    Goto, Keisuke
    Sakamoto, Yuki
    Iwane, Kyohsuke
    Nishida, Kensuke
    Hashimoto, Kunihiro
    Asami, Akihiro
    Iwamoto, Hideo
    Hayashi, Tetsutaro
    Takemoto, Kenshiro
    Naito, Miki
    Miyamoto, Shunsuke
    Sekino, Yohei
    Kitano, Hiroyuki
    Goriki, Akihiro
    Hieda, Keisuke
    Hinata, Nobuyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, : 524 - 530
  • [29] Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Flaig, Thomas W.
    Moon, Helen H.
    Friedlander, Terence W.
    Mar, Nataliya
    McKay, Rana R.
    Srinivas, Sandy
    Gravis, Gwenaelle
    Ramamurthy, Chethan
    Bupathi, Manojkumar
    Bracarda, Sergio
    Wright, Phoebe
    Hepp, Zsolt
    Carret, Anne-Sophie
    Yu, Yao
    Dillon, Ryan
    Kataria, Ritesh
    Beaumont, Jennifer L.
    Purnajo, Intan
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1403 - 1414
  • [30] Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
    Rizzo, Mimma
    Morelli, Franco
    Urun, Yueksel
    Buti, Sebastiano
    Park, Se Hoon
    Bourlon, Maria T.
    Grande, Enrique
    Massari, Francesco
    Landmesser, Johannes
    Poprach, Alexandr
    Takeshita, Hideki
    Roviello, Giandomenico
    Myint, Zin W.
    Popovic, Lazar
    Soares, Andrey
    Abahssain, Halima
    Giannatempo, Patrizia
    Molina-Cerrillo, Javier
    Incorvaia, Lorena
    Salah, Samer
    Zeppellini, Annalisa
    Monteiro, Fernando Sabino Marques
    Porta, Camillo
    Gupta, Shilpa
    Santoni, Matteo
    CANCER MEDICINE, 2025, 14 (04):
12345